{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:56:21Z","timestamp":1791186981768,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373161"],"award-info":[{"award-number":["82373161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05703-x","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:33:17Z","timestamp":1786955597000},"page":"4797-4812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["XYLB promotes malignant behaviors of triple-negative breast cancer via SUSD3 upregulation"],"prefix":"10.1007","volume":"481","author":[{"given":"Chen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"5703_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"key":"5703_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13:674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66","journal-title":"Nat Rev Clin Oncol"},{"key":"5703_CR3","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014","journal-title":"J Clin Invest"},{"key":"5703_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA (2022) Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer 8:95. https:\/\/doi.org\/10.1038\/s41523-022-00468-0","journal-title":"NPJ Breast Cancer"},{"key":"5703_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1642521","volume":"15","author":"MR Brogna","year":"2025","unstructured":"Brogna MR, Ferrara G, Varone V, Montone A, Fava A, Schiano MR, Del Sesto M, Pizza N, Prota A, Barra C, Collina F (2025) Liquid biopsy in triple-negative breast cancer: a promising tool for diagnosis, prognosis, and treatment monitoring. Front Oncol 15:1642521. https:\/\/doi.org\/10.3389\/fonc.2025.1642521","journal-title":"Front Oncol"},{"key":"5703_CR6","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"key":"5703_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov 9:176\u2013198. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1177","journal-title":"Cancer Discov"},{"key":"5703_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3892\/etm.2015.2489","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Xiao Y, Wei W, Guo JX, Liu YC, Huang XH, Zhang RX, Wu YJ, Zhou J (2015) Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. Exp Ther Med 10:379\u2013385. https:\/\/doi.org\/10.3892\/etm.2015.2489","journal-title":"Exp Ther Med"},{"issue":"Suppl 6","key":"5703_CR9","doi-asserted-by":"publisher","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","volume":"23","author":"F Andre","year":"2012","unstructured":"Andre F, Zielinski CC (2012) Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23(Suppl 6):vi46-51. https:\/\/doi.org\/10.1093\/annonc\/mds195","journal-title":"Ann Oncol"},{"key":"5703_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"5703_CR11","doi-asserted-by":"publisher","DOI":"10.2174\/0118715206402646251115102627","author":"A Das","year":"2026","unstructured":"Das A, Lather V (2026) Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress. Anticancer Agents Med Chem. https:\/\/doi.org\/10.2174\/0118715206402646251115102627","journal-title":"Anticancer Agents Med Chem"},{"key":"5703_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"Patra KC, Hay N (2014) The pentose phosphate pathway and cancer. Trends Biochem Sci 39:347\u2013354. https:\/\/doi.org\/10.1016\/j.tibs.2014.06.005","journal-title":"Trends Biochem Sci"},{"key":"5703_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB (2016) The Emerging Hallmarks of Cancer Metabolism. Cell Metab 23:27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006","journal-title":"Cell Metab"},{"key":"5703_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ncb2172","volume":"13","author":"P Jiang","year":"2011","unstructured":"Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, Yang X (2011) p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 13:310\u2013316. https:\/\/doi.org\/10.1038\/ncb2172","journal-title":"Nat Cell Biol"},{"key":"5703_CR15","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1074\/jbc.M112.427997","volume":"288","author":"RD Bunker","year":"2013","unstructured":"Bunker RD, Bulloch EM, Dickson JM, Loomes KM, Baker EN (2013) Structure and function of human xylulokinase, an enzyme with important roles in carbohydrate metabolism. J Biol Chem 288:1643\u20131652. https:\/\/doi.org\/10.1074\/jbc.M112.427997","journal-title":"J Biol Chem"},{"key":"5703_CR16","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gutjnl-2025-336415","volume":"75","author":"L Zhou","year":"2026","unstructured":"Zhou L, Nie J, Feng Z, Li R, Zhang P, Lin S, Zhang Y, Rieder F, Chen C, Chen M, Mao R (2026) Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn\u2019s disease. Gut 75:905\u2013919. https:\/\/doi.org\/10.1136\/gutjnl-2025-336415","journal-title":"Gut"},{"key":"5703_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.cmet.2025.06.011","volume":"37","author":"T Shi","year":"2025","unstructured":"Shi T, Shao J, Ding Y, Tang H, Tan X, Zhou S, Yu S, Wang X, Yu G, Feng N, Wang X (2025) Xylulose 5-phosphate fosters sustained antitumor activity of progenitor-like exhausted SLC35E2(+) CD8(+) T effector cells. Cell Metab 37:1835\u20131851e10. https:\/\/doi.org\/10.1016\/j.cmet.2025.06.011","journal-title":"Cell Metab"},{"key":"5703_CR18","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1073\/pnas.0730817100","volume":"100","author":"T Kabashima","year":"2003","unstructured":"Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K (2003) Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc Natl Acad Sci U S A 100:5107\u20135112. https:\/\/doi.org\/10.1073\/pnas.0730817100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5703_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12013-014-0480-9","volume":"72","author":"Z Yu","year":"2015","unstructured":"Yu Z, Jiang E, Wang X, Shi Y, Shangguan AJ, Zhang L, Li J (2015) Sushi Domain-Containing Protein 3: A Potential Target for Breast Cancer. Cell Biochem Biophys 72:321\u2013324. https:\/\/doi.org\/10.1007\/s12013-014-0480-9","journal-title":"Cell Biochem Biophys"},{"key":"5703_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/onc.2013.553","volume":"34","author":"I Moy","year":"2015","unstructured":"Moy I, Todorovic V, Dubash AD, Coon JS, Parker JB, Buranapramest M, Huang CC, Zhao H, Green KJ, Bulun SE (2015) Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells. Oncogene 34:323\u2013333. https:\/\/doi.org\/10.1038\/onc.2013.553","journal-title":"Oncogene"},{"key":"5703_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1521965","volume":"16","author":"F Zhong","year":"2025","unstructured":"Zhong F, Mao S, Peng S, Li J, Xie Y, Xia Z, Chen C, Sun A, Zhang S, Wang S (2025) Exploration of SUSD3 in pan-cancer: studying its role, predictive analysis, and biological significance in various malignant tumors in humans. Front Immunol 16:1521965. https:\/\/doi.org\/10.3389\/fimmu.2025.1521965","journal-title":"Front Immunol"},{"key":"5703_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12094-024-03641-y","volume":"27","author":"YM Dong","year":"2025","unstructured":"Dong YM, Bao GQ (2025) Characterization of SUSD3 as a novel prognostic biomarker and therapeutic target for breast cancer. Clin Transl Oncol 27:935\u2013949. https:\/\/doi.org\/10.1007\/s12094-024-03641-y","journal-title":"Clin Transl Oncol"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05703-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05703-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:45:25Z","timestamp":1791186325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05703-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5703"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05703-x","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of paraffin-embedded human tissue specimens was reviewed and approved by the Ethics Committee of Shanghai Outdo Biotech Co., Ltd. (ethics approval reference\/project No. SHXC2021YF01). All procedures involving human tissue specimens were conducted in accordance with applicable institutional requirements and the principles of the Declaration of Helsinki. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Bojin Biotechnology (approval No. BG-AMS-250610-CH01-Y) and were conducted in accordance with relevant institutional and national guidelines. The animal facility operated under animal use permit No. SYXK (Yue) 2023\u2009\u2212\u20090343.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0\n                      \n                      k and l.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}